DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase

Christophe Noll, Chris Planque, Clémentine Ripoll et al. · 2009

Read DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase by Christophe Noll, Chris Planque, Clémentine Ripoll et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007540.txt.

Description

Christophe Noll and colleagues published a study in PLOS ONE in 2009 on a gene linked to Down syndrome and its effect on metabolism. High homocysteine in the blood raises the risk of clogged arteries. People with Down syndrome, oddly, seem protected from atherosclerosis. The gene DYRK1A sits in the Down syndrome region and is overproduced there. The team tested its role in mouse models carrying extra copies of it.

DYRK1A emerged as a determinant of the methionine-homocysteine cycle. That cycle controls the very metabolite tied to artery risk. A gene that tunes the cycle could explain the Down syndrome protection. The finding links a chromosome-21 kinase to a classic cardiovascular pathway. It also suggests the cycle could be adjusted by targeting the enzyme. The study connects two distant literatures: Down syndrome biology and heart disease.

Catalog record

CREATORChristophe Noll, Chris Planque, Clémentine Ripoll et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007540

Browse the full library · About the Tower of Babel